21/12/2014 01:51:59 Free Membership Login

Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
12/18/201412:00PMGLOBENymox Announces $1.07 Million Financing
HASBROUCK HEIGHTS, N.J., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53. The proceeds will be used as additional funding for the Company's activities... More...>>
12/12/20144:04PMGLOBEEQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class Action Deadline -- NYMX
NEW YORK, Dec. 12, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action. To join the Nymox class action... More...>>
12/11/20143:09PMGLOBESHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its ...
NEW YORK, Dec. 11, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (Nasdaq:NYMX) securities between January... More...>>
12/09/201410:00PMBWSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceu...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq: NYMX) common... More...>>
12/08/20149:11AMPRNUSLaw Offices of Marc S. Henzel Announces Securities Class Action Periods
Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire MERION, Pa., Dec. 8, 2014 MERION, Pa., Dec. 8, 2014 /PRNewswire/ -- The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following... More...>>
12/04/20141:21PMPRNUSLifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, ...
Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., and Spansion, Inc. PR Newswire NEW YORK, Dec. 4, 2014 NEW YORK, Dec. 4, 2014 /PRNewswire/ -- Avanir Pharmaceuticals... More...>>
11/26/20142:31PMPRNUSCohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information
Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information PR Newswire PHILADELPHIA, Nov. 26, 2014 PHILADELPHIA, Nov. 26, 2014 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating potential claims on behalf of investors who purchased Nymox... More...>>
07/22/20149:30AMGLOBENymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., July 22, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce new positive efficacy data for U.S. Study NX02-0022, the Company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period... More...>>
07/15/20149:30AMGLOBENymox Announces Completion of Enrollment for Second BPH Re-Injection Study
HASBROUCK HEIGHTS, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of enrollment for Study NX02-0022, the Company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate (benign prostatic... More...>>
06/17/201410:00AMGLOBENymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
HASBROUCK HEIGHTS, N.J., June 17, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report new data supporting the positive sexual functional preservation profile of NX-1207, the Company's lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic... More...>>
06/11/201410:15AMGLOBENymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
HASBROUCK HEIGHTS, N.J., June 11, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce new clinical data supporting the positive safety profile of NX-1207, the Company's lead compound in late Phase 3 testing for prostate enlargement (BPH or benign prostate hyperplasia). Recent... More...>>
05/21/20149:50AMGLOBENymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment
HASBROUCK HEIGHTS, N.J., May 21, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report new positive data confirming the advantageous side effect profile of the Company's lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Company's recently... More...>>
05/15/20149:45AMGLOBENymox Reports First Quarter 2014 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2014. Nymox reported a net loss of $2,592,816, or $0.07 per share for the quarter ended March 31, 2014, compared to $1,093,906, or $0.03 per share for the... More...>>
05/13/20149:45AMGLOBENymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels
HASBROUCK HEIGHTS, N.J., May 13, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new study findings showing that the Company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels... More...>>
05/08/201410:30AMGLOBENymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
HASBROUCK HEIGHTS, N.J., May 8, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the last enrolled patient has completed participation in the Company's pivotal Phase 3 clinical trial, NX02-0018. The NX02-0018 trial is the second of two pivotal prospective double blind placebo-controlled... More...>>
05/06/201410:00AMGLOBENymox Announces Positive New Prostate Cancer Clinical Trial Results
HASBROUCK HEIGHTS, N.J., May 6, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results... More...>>
04/30/20149:30AMGLOBENymox Reports Top-Line Results for Localized Prostate Cancer Study
HASBROUCK HEIGHTS, N.J., April 30, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report top-line results from the company's 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients... More...>>
03/14/20141:00PMGLOBENymox Reports 2013 Financial Results
HASBROUCK HEIGHTS, N.J., March 14, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the... More...>>
02/05/20142:00PMGLOBENymox Announces Appointment of Andre Monette
HASBROUCK HEIGHTS, N.J., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company. Mr. Monette, who is a Chartered Professional Accountant and Chartered Financial Analyst, brings to the company extensive... More...>>
01/28/201411:30AMGLOBENymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
HASBROUCK HEIGHTS, N.J., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided updates on pivotal Phase 3 development activities for NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nymx141221 01:52